2020年基因组学前瞻：基因组研究及临床趋势（英文版）_4页

Genomics 2020: Research and Clinical Trends to Watch

Core Content

Genomics has experienced significant technological advancements over the past three decades, leading to transformative changes in both research and clinical settings. The development of key technologies such as PCR, microarrays, and next-generation sequencing (NGS) has enabled more comprehensive and cost-effective genomic analysis. The first human genome was sequenced in 2003 at a cost of around $3 billion, but NGS has since reduced this cost to under $1,000 per genome, making genomic research and clinical applications more accessible.

These advancements have driven the integration of genomics into clinical practice, particularly in areas such as infectious disease, cancer, and inherited disease, where genomic techniques offer improved sensitivity, faster turnaround times, and more informative results compared to traditional methods.

Main Trends and Key Insights

1. Further Adoption of NGS

• NGS is becoming more widely adopted in both high- and low-throughput research settings.
• It is also expanding into clinical markets, especially in oncology, reproductive health, and genetics.
• Innovations such as RNA-sequencing and long-read technologies are broadening the scope of research and clinical applications.

2. Moving to Single-Cell Biology

• Single-cell analysis is emerging as a way to overcome the limitations of traditional "average measurements."
• Technologies such as sample enrichment, molecular indexing, and highly sensitive tools (e.g., NGS, digital PCR) enable researchers to study individual cells and their heterogeneity.
• This approach provides deeper insights into biological processes like tumor evolution and normal development.

3. Emergence of RNA Biology

• RNA is increasingly recognized as a more biologically relevant marker than DNA mutations.
• RNA sequencing and RNA in situ hybridization (RNA-ISH) are enabling the study of the entire transcriptome and non-coding RNA.
• These tools are helping to bridge the gap between DNA and functional outcomes in research and clinical settings.

4. Molecular Stethoscope

• The concept of a "molecular stethoscope" refers to the ability to detect and analyze cell-free DNA (cfDNA) in circulation.
• cfDNA has been used in noninvasive prenatal testing (NIPT) and is now being applied to cancer detection, pathogen identification, and transplant monitoring.
• Integration with single-cell genomics allows for the analysis of rare cell populations, enhancing diagnostic capabilities.

5. Mendelian Genetic Testing

• Mendelian genetic testing is improving the reproductive health diagnostic paradigm by enabling carrier screening and prenatal analysis.
• It extends to in vitro fertilization (IVF) and in utero testing for inherited diseases.
• Trio testing (mother, father, and child) provides more accurate insights into inheritance patterns and disease predispositions.

6. Testing Moves Closer to the Patient

• Technological advancements are enabling the decentralization of genomic testing from centralized labs to community hospitals and physician offices.
• These innovations include automated workflows, smaller instrument footprints, and simplified result interpretation.
• Continued development of technologies that allow analysis from crude samples will further expand point-of-care applications.

7. Genotype Meets Phenotype

• Integration of genomic data with phenotype and outcome data is critical for deriving clinical significance from genetic variation.
• Efforts such as the 1000 Genomes Project and The Cancer Genome Atlas have generated large genomic datasets, but they often lack associated phenotype data.
• Initiatives like ASCO CancerLinQ aim to link genotype with phenotype, improving the understanding of genetic variation in disease contexts.

8. Scaling the Research Experiment

• As more genomic biomarkers are discovered, their prevalence tends to decrease, necessitating larger-scale research.
• Large-scale studies such as the Million Veteran Program are expected to play a crucial role in understanding genetic diversity across populations.
• These studies will help identify rare biomarkers and their associations with disease.

9. Clinical Trial Baskets

• The development of targeted therapies based on specific genomic biomarkers is leading to the creation of clinical trial baskets.
• These baskets allow for the enrollment of patients with rare or specific genetic profiles, improving the efficiency of drug development.
• Early examples such as the Lung Cancer Master Protocol show the potential for coordinated efforts to streamline patient recruitment.

Key Technology Innovators

Conclusion

The genomics revolution is accelerating, with nine key trends shaping the future of research and clinical applications. These trends are driven by technological innovation and are creating significant opportunities for IVD companies, reference laboratories, life science tools providers, and bioinformatics vendors. As the field continues to evolve, the integration of genomic data with clinical and phenotypic information will be essential for realizing the full potential of genomics in healthcare.